Table 1.
Baseline Characteristics for Nonfasting and Fasting Participants
| Baseline Characteristics |
Nonfasting (n=5262) |
Fasting (n=10 135) |
P-Value |
|---|---|---|---|
| Age, years | 68.2 (7.1) | 67.9 (6.9) | 0.003 |
| Women, % | 51.6 | 50.5 | 0.1926 |
| Time Since Last Meal, hours | 2.7 (1.7) | 12.2 (2.2) | <0.0001 |
| Race a, % | |||
| White | 85.7 | 80.2 | |
| Black | 11.9 | 16.9 | <0.0001 |
| Other | 2.4 | 3.0 | |
| Smoking, % | |||
| Never | 51.5 | 52.0 | |
| Past | 43.0 | 41.8 | 0.2028 |
| Current | 5.5 | 6.2 | |
| Body Mass Index, kg/m2 | 27.2 (5.2) | 28.2 (5.7) | <0.0001 |
| Hypertension, % | 49.4 | 55.0 | <0.0001 |
| Diabetes, % | 10.8 | 14.5 | <0.0001 |
| Postmenopausal Hormone Use, % | |||
| Current | 13.5 | 11.6 | 0.0027 |
| Past | 48.4 | 47.1 | 0.0027 |
| None | 37.7 | 41.3 | |
| Cholesterol Medication Use b, % | 34.3 | 42.2 | <0.0001 |
Values displayed represent mean with standard deviation (SD) for continuous variables or percentage (%) for categorical variables. Statistical significance was assessed by t-tests for continuous variables and chi-squared analysis for categorical variables.
a
Other race includes American Indian/Alaskan native, Pacific islander/Hawaiian native, Asian and more than one race or other designation.
b
94% of participants on cholesterol lowering medication reported a statin as the cholesterol lowering drug. 6% were on non-statin agents.